BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 8297546)

  • 1. Pharmacokinetics of fluvastatin and specific drug interactions.
    Smith HT; Jokubaitis LA; Troendle AJ; Hwang DS; Robinson WT
    Am J Hypertens; 1993 Nov; 6(11 Pt 2):375S-382S. PubMed ID: 8297546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():11-5. PubMed ID: 8729584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications of the biopharmaceutical properties of fluvastatin.
    Deslypere JP
    Am J Cardiol; 1994 May; 73(14):12D-17D. PubMed ID: 8198018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
    Dujovne CA; Davidson MH
    Am J Med; 1994 Jun; 96(6A):37S-40S. PubMed ID: 8017465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin.
    Smit JW; Wijnne HJ; Schobben F; Sitsen A; de Bruin TW; Erkelens DW
    Am J Cardiol; 1995 Jul; 76(2):89A-96A. PubMed ID: 7604808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
    Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
    Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A.
    Park JW; Siekmeier R; Lattke P; Merz M; Mix C; Schüler S; Jaross W
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):351-61. PubMed ID: 11907637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL.
    Barilla D; Prasad P; Hubert M; Gumbhir-Shah K
    Biopharm Drug Dispos; 2004 Mar; 25(2):51-9. PubMed ID: 14872552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition.
    Bard JM; Dallongeville J; Hagen E; Pfister P; Ose L; Fruchart JC; Duriez P
    Metabolism; 1995 Nov; 44(11):1447-54. PubMed ID: 7476333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of fluvastatin.
    Scripture CD; Pieper JA
    Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of alcohol and fluvastatin on lipid metabolism and hepatic function.
    Smit JW; Wijnne HJ; Schobben F; Sitsen A; De Bruin TW; Erkelens DW
    Ann Intern Med; 1995 May; 122(9):678-80. PubMed ID: 7702230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey.
    Tse FL; Smith HT; Ballard FH; Nicoletti J
    Biopharm Drug Dispos; 1990; 11(6):519-31. PubMed ID: 2207302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose of fluvastatin sodium (XU62-320), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, lowers plasma cholesterol levels in homozygous Watanabe-heritable hyperlipidemic rabbits.
    Kurokawa J; Hayashi K; Toyota Y; Shingu T; Shiomi M; Kajiyama G
    Biochim Biophys Acta; 1995 Oct; 1259(1):99-104. PubMed ID: 7492622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia.
    Sabia H; Prasad P; Smith HT; Stoltz RR; Rothenberg P
    J Cardiovasc Pharmacol; 2001 May; 37(5):502-11. PubMed ID: 11336101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers.
    Tse FL; Jaffe JM; Troendle A
    J Clin Pharmacol; 1992 Jul; 32(7):630-8. PubMed ID: 1640002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluvastatin in familial hypercholesterolemia: a cohort analysis of the response to combination treatment.
    Muratti EN; Peters TK; Leitersdorf E
    Am J Cardiol; 1994 May; 73(14):30D-38D. PubMed ID: 8198022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.